Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil

Tuberculosis

Volumn 101, Issue , 2016, Pages 15-24

  Heinrich, Melissa M ^a   Zembrzuski, Verônica M ^a   Ota, Marcos M ^b   Sacchi, Flavia P ^c   Teixeira, Raquel L F ^a   Cabello Acero, Pedro H ^a,d   Cunha, Geraldo Marcelo ^a   Souza Santos, Reinaldo ^a   Croda, Julio ^a,b   Basta, Paulo C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDADE FEDERAL DA GRANDE DOURADOS   (Brazil)

^c FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^d Inst Ciencias Exatas e da Natureza   (Brazil)

Author keywords

Adverse drug reactions; Hepatotoxicity; Indigenous; Pharmacogenetics; Tuberculosis

Indexed keywords

CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE M1; LIVER ENZYME; TUBERCULOSTATIC AGENT; ARYLAMINE ACETYLTRANSFERASE; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE TRANSFERASE; NAT2 PROTEIN, HUMAN;

ACETYLATION; ADOLESCENT; ADULT; ARTICLE; BRAZIL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; EPIDEMIOLOGICAL DATA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GROUPS BY AGE; HUMAN; INCIDENCE; INDIGENOUS PEOPLE; LIVER TOXICITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS; YOUNG ADULT; AGED; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; GENETIC PREDISPOSITION; GENETICS; INFANT; PRESCHOOL CHILD; TUBERCULOSIS, PULMONARY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BRAZIL; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2E1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INCIDENCE; INFANT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84983028458     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2016.07.006     Document Type: Article

References (83)

1. [1] Barreto, M.L., Teixeira, M.G., Bastos, F.I., Ximenes, R.A., Barata, R.B., Rodrigues, L.C., Successes and failures in the control of infectious diseases in Brazil: social and environmental context, policies, interventions, and research needs. Lancet 377 (2011), 1877–1889, 10.1016/S0140-6736(11)60202-X.
2. [2] de Silva Antunes, R., Pinto, M., Trajman, A.F., Patient costs for the diagnosis of tuberculosis in Brazil: comparison of Xpert MTB/RIF and smear microscopy. Int J Tuberc Lung Dis 18 (2014), 547–551, 10.5588/ijtld.13.0637.
3. [3] de Albuquerque Mde, F., Ximenes, R.A., Lucena-Silva, N., de Souza, W.V., Dantas, A.T., Dantas, O.M., Rodrigues, L.C., Factors associated with treatment failure, dropout, and death in a cohort of tuberculosis patients in Recife, Pernambuco State, Brazil. Cad Saúde Publica 23 (2007), 1573–1582.
4. [4] Nava-Aguilera, E., Andersson, N., Harris, E., Mitchell, S., Hamel, C., Shea, B., López-Vidal, Y., Villegas-Arrizón, A., Morales-Pérez, A., Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 13 (2009), 17–26.
5. [5] Orofino, R.D., Brasil, P.E., Trajman, A., Schmaltz, C.A., Dalcolmo, M., Rolla, V.C., Preditores dos desfechos do tratamento da tuberculose (Trans.) Predictors of tuberculosis treatment outcomes J Bras Pneumol 38 (2012), 88–97, 10.1590/S1806-37132012000100013.
6. [6] Paixão, L.M.M., Gontijo, E.D., Profile of notified tuberculosis cases and factors associated with treatment dropout. Rev Saúde Pública 41 (2007), 205–213, 10.1590/S0034-89102007000200006.
7. [7] Jeon, C.Y., Murray, M.B., Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med, 5, 2008, e152, 10.1371/journal.pmed.0050152.
8. [8] Lacerda, S.N., Temoteo, R.C., Figueiredo, T.M., Luna, F.D., Sousa, M.A., Abreu, L.C., Individual and social vulnerabilities upon acquiring tuberculosis: a literature systematic review. Int Arch Med, 2014, 10.1186/1755-7682-7-35.
9. [9] Narasimhan, P., Wood, J., MacIntyre, C.R., Mathai, D., Risk factors for tuberculosis. Pulm Med, 2013, 2013, 828939, 10.1155/2013/828939.
10. [10] World Health Organization, Global tuberculosis report. WHO report, 2014.
11. [11] Tollefson, D., Bloss, E., Fanning, A., Redd, J.T., Barker, K., McCray, E., Burden of tuberculosis in indigenous peoples globally: a systematic review. Int J Tuber Lung Dis 17 (2013), 1139–1150, 10.5588/ijtld.12.0385.
12. [12] Bloss, E., Holtz, T.H., Jereb, J., Redd, J.T., Podewils, L.J., Cheek, J.E., McCray, E., Tuberculosis in indigenous peoples in the U.S., 2003–2008. Public Health Rep 126 (2011), 677–689.
13. [13] Robertus, L.M., Konstantinos, A., Hayman, N.E., Paterson, D.L., Tuberculosis in the Australian Indigenous population: history, current situation and future challenges. Aust N Z J Public Health 35 (2011), 6–9, 10.1111/j.1753-6405.2010.00663.x.
14. [14] Sánchez-Pérez, H.J., Díaz-Vázquez, A., Nájera-Ortiz, J.C., Balandrano, S., Martín-Mateo, M., Multidrug-resistant pulmonary tuberculosis in Los Altos, Selva and Norte regions, Chiapas, Mexico. Int J Tuberc Lung Dis 14:1 (2000), 34–39.
15. [15] Canadian Tuberculosis Committee, Housing conditions that serve as risk factors for tuberculosis infection and disease. An Advisory Committee Statement (ACS). Can Commun Dis Rep 33 (2007), 1–33.
16. [16] Basta, P.C., Coimbra, C.E. Jr., Camacho, L.A., Santos, R.V., Risk of tuberculous infection in an indigenous population from Amazonia, Brazil. Int J Tuber Lung Dis 10 (2006), 1354–1359, 10.5216/rpt.v45i1.40136.
17. [17] Basta, P.C., Marques, M., Oliveira, R.L., Cunha, E.A., Resendes, A.P., Souza-Santos, R., Desigualdades sociais e tuberculose: análise segundo raça/cor, Mato Grosso do Sul (Trans.) Social inequalitites and tuberculosis: an analysis by race/color in Mato Grosso do Sul, Brazil Rev Saude Publica 47 (2013), 854–864, 10.1590/S0034-8910.2013047004628.
18. [18] Barbosa, T., Benigno, A., Farre, L., Prat, J.G., Barral-Netto, M., Arruda, S., Tuberculosis among Yanomami communities from Alto Rio Negro, state of Amazonas, Brazil, 1990 to 2002. Enf Emerg 10 (2008), 138–143.
19. [19] Marques, A.M., Pompilio, M.A., Santos, S.C., Garnês, S.J., Cunha, R.V., Tuberculosis among Brazilian indigenous individuals aged less than 15 years-old in State of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop 43 (2010), 700–704, 10.1590/S1806-37132013000100012.
20. [20] Belo, E.N., Orellana, J.D., Levino, A., Basta, P.C., Tuberculose nos municípios amazonenses da fronteira Brasil-Colômbia-Peru-Venezuela: situação epidemiológica e fatores associados ao abandono (Trans.) Tuberculosis in Amazonian municipalities of the Brazil-Colombia-Per-Benezuela border: epidemiological situation and risk factors associated with treatment default Rev Panam Salud Publica 34 (2013), 321–329.
21. [21] Cunha, E.A., Ferrazoli, L., Riley, L.W., Basta, P.C., Honer, M.R., Maia, R., Incidence and transmission patterns of tuberculosis among indigenous populations in Brazil. Mem Inst Oswaldo Cruz 109 (2014), 108–113, 10.1590/0074-0276130082.
22. [22] Breen, R.A., Miller, R.F., Gorsuch, T., Smith, C.J., Schwenk, A., Holmes, W., Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 61 (2006), 791–794, 10.1136/thx.2006.058867.
23. [23] Ferreira, A.C., Silva Júnior, J.L., Conde, M.B., Rabahi, M.F., Clinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goiânia. Braz J Bras Pneumol 39 (2013), 76–83, 10.1590/S1806-37132013000100011.
24. [24] Vieira, D.E., Gomes, M., Efeitos adversos no tratamento da tuberculose: experiência em serviço ambulatorial de um hospital-escola na cidade de São Paulo (Trans.) Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil J Bras Pneumol 34 (2008), 1049–1055, 10.1590/S1806-37132008001200010.
25. [25] Lima Mde, F., Melo, H.R., Hepatotoxicidade das drogas antituberculose entre pacientes coinfectados HIV/tuberculose (Trans.) Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis Cad Saúde Publica 28 (2012), 698–708, 10.1590/S0102-311X2012000400009.
26. [26] Arbex, M.A., Varella Mde, C., Siqueira, H.R., Mello, F.A., Drogas antituberculose: Interações medicamentosas, efeitos adversos e utilização em situações especiais. Parte 1: Fármacos de primeira linha (Trans.) Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs J Bras Pneumol 36 (2010), 626–640, 10.1590/S1806-37132010000500016.
27. [27] Cho, H.J., Koh, W.J., Ryu, Y.J., Ki, C.S., Nam, M.H., Kim, J.W., Kim, J.W., Lee, S.Y., Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberc (Edinb) 87 (2007), 551–556, 10.1016/j.tube.2007.05.012.
28. [28] Mitchell, J.R., Snodgrass, W.R., Gillette, J.R., The role of biotransformation in chemical-induced liver injury. Environ Health Perspect 15 (1976), 27–38.
29. [29] Roy, P.D., Majumder, M., Roy, B., Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 9 (2008), 311–321, 10.2217/14622416.9.3.311.
30. [30] Runge-Morris, M., Feng, Y., Zangar, R.C., Novak, R.F., Effects of hydrazine, phenelzine, and hydralazine treatmenton rat hepatic and renal drug-metabolizing enzyme expression. Drug Metab Dispos 24 (1996), 734–737, 10.1371/journal.pone.0047769.
31. [31] Sharma, S.K., Jha, B.K., Sharma, A., Sreenivas, V., Upadhyay, V., Jaisinghani, C., Singla, R., Mishra, H.K., Soneja, M., Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 18 (2014), 588–593, 10.5588/ijtld.13.0344.
32. [32] Strange, R.C., Jones, P.W., Fryer, A.A., Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 112–113 (2000), 357–363.
33. [33] Kubota, R., Ohno, M., Hasunuma, T., Iijima, H., Azuma, J., Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol 63 (2007), 927–933, 10.1007/s00228-007-0333-1.
34. [34] Castillejos-López Mde, J., García-Sancho, M.C., Quiñones-Falconi, F., Pérez-Padilla, J.R., Cytochrome P450 and NAT2 polymorphisms and drug metabolism in DOTS. Rev Invest Clin 60 (2008), 47–57.
35. [35] Possuelo, L.G., Castelan, J.A., de Brito, T.C., Ribeiro, A.W., Cafrune, P.I., Picon, P.D., Santos, A.R., Teixeira, R.L., Gregianini, T.S., Hutz, M.H., Rossetti, M.L., Zaha, A., Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64 (2008), 673–681, 10.1007/s00228-008-0484-8.
36. [36] Teixeira, R.L., Morato, R.G., Cabello, P.H., Muniz, L.M., Moreira Ada, S., Kritski, A.L., Mello, F.C., Suffys, P.N., Miranda, A.B., Santos, A.R., Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 106 (2011), 716–724.
37. [37] Instituto Brasileiro de Geografia e Estatística. [internet homepage]. Cidades [accessed 20th February 2013]. Available www.ibge.gov.br/cidadesat/topwindow.htm.
38. [38] Instituto Brasileiro de Geografia e Estatística. [internet homepage]. População Indígena. [accessed 24th february 2013] http://indigenas.ibge.gov.br/graficos-e-tabelas.
39. [39] Croda, M.G., Trajber, Z., Lima Rda, C., Croda, J., Tuberculosis control in a highly endemic indigenous community in Brazil. Trans R Soc Trop Med Hyg 106 (2012), 223–229.
40. [40] Sacchi, F.P., Croda, M.G., Estevan, A.O., Ko, A.I., Croda, J., Sugar cane manufacturing is associated with tuberculosis in an indigenous population in Brazil. Trans R Soc Trop Med Hyg 107 (2013), 152–157, 10.1093/trstmh/trs089.
41. [41] Masur, J., Monteiro, M.G., Validation of the ‘‘CAGE’’ alcoholism screening test in a Brazilian psychiatric inpatient hospital setting. Braz J Med Biol Res 16 (1983), 215–218.
42. [42] Conde, M.B., Melo, F.A., Marques, A.M., Cardoso, N.C., Pinheiro, V.G., Dalcin Pde, T.R., Machado Junior, A., Lemos, A.C., Netto, A.R., Durovni, B., Sant'Anna, C.C., Lima, D., Capone, D., Barreira, D., Matos, E.D., Mello, F.C., David, F.C., Marsico, G., Afiune, J.B., Silva, J.R., Jamal, L.F., Telles, M.A., Hirata, M.H., Dalcolmo, M.P., Rabahi, M.F., Cailleaux-Cesar, M., Palaci, M., Morrone, N., Guerra, R.L., Dietze, R., Miranda, S.S., Cavalcante, S.C., Nogueira, S.A., Nonato, T.S., Martire, T., Galesi, V.M., Dettoni Vdo, V., BTA Committee on Tuberculosis; BTA Guidelines on Tuberculosis Work Group. III Brazilian Thoracic association guidelines on tuberculosis., 35, 2009, 1018–1048, 10.1590/S1806-37132009001000011.
43. [43] Bénichou, C., Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11:2 (1990), 272–276.
44. [44] Teixeira, R.L., Miranda, A.B., Pacheco, A.G., Lopes, M.Q., Fonseca-Costa, J., Rabahi, M.F., Melo, H.M., Kritski, A.L., Mello, F.C., Suffys, P.N., Santos, A.R., Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat Res 624 (2007), 31–40, 10.1016/j.mrfmmm.2007.03.015.
45. [45] Marra, F., Marra, C.A., Bruchet, N., Richardson, K., Moadebi, S., Elwood, R.K., Elwood, R.K., Fitzgerald, J.M., Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 11 (2007), 868–875.
46. [46] Shu, C.C., Lee, C.H., Lee, M.C., Wang, J.Y., Yu, C.J., Lee, L.N., Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 17 (2013), 934–939, 10.5588/ijtld.12.0782.
47. [47] Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., Menzies, D., Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167 (2003), 1472–1477, 10.1164/rccm.200206-626OC.
48. [48] Tostmann, A., Boeree, M.J., Harries, A.D., Sauvageot, D., Banda, H.T., Zijlstra, E.E., Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. Trop Med Int Health 12 (2007), 852–855, 10.1111/j.1365-3156.2007.01871.x.
49. [49] Kim, S.Y., Lee, S.M., Yim, J.J., Yoo, C.G., Kim, Y.W., Han, S.K., Yang, S.C., Treatment response and adverse reactions in older tuberculosis patients with immuno compromising comorbidities. Yonsei Med J 54 (2013), 1227–1233, 10.3349/ymj.2013.54.5.1227.
50. [50] García-Cortés, M., Stephens, C., Lucena, M.I., Fernández-Castañer, A., Andrade, R.J., Spanish group for the study of drug-induced liver disease. J Hepatol 55 (2011), 683–691, 10.1016/j.jhep.2011.02.007.
51. [51] Gulbay, B.E., Guorkan, O.U., Yıldız, A.O., Onen, Z.P., Erkekol, F.O., Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 100 (2006), 1834–1842, 10.1016/j.rmed.2006.01.014.
52. [52] Codecasa, L.R., Murgia, N., Ferrarese, M., Delmastro, M., Repossi, A.C., Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis 17 (2013), 903–908, 10.5588/ijtld.12.0677.
53. [53] Marques, A.M., da Cunha, R.V., A medicação assistida e os índices de cura de tuberculose e de abandono de tratamento na população indígena Guaraní-Kaiowá no Município de Dourados, Mato Grosso do Sul, Brasil (Trans.) Assisted treatment and tuberculosis cure and treatment dropout rates in the Guaraní-Kaiowa Indian nation in the municipality of Dourados, Mato Grosso do Sul, Brazil Cad Saude Publica 19 (2003), 1405–1411, 10.1590/S0102-311X2003000500019.
54. [54] Santos, S.C., Marques, A.M., Oliveira, R.L., Cunha, R.V., Scoring system for the diagnosis of tuberculosis in indigenous children and adolescents under 15 years of age in the state of Mato Grosso do Sul. Braz J Bras Pneumol 39 (2013), 84–91, 10.1590/S1806-37132013000100012.
55. [55] Horta, B.L., Santos, R.V., Welch, J.R., Cardoso, A.M., Dos Santos, J.V., Assis, A.M., Lira, P.C., Coimbra, C.E. Jr., Nutritional status of indigenous children: findings from the first national survey of indigenous people's health and nutrition in Brazil. Int J Equity Health, 12, 2013, 23, 10.1186/1475-9276-12-23 http://dx.doi.org/10.1590/S0102-311X2013000800006.
56. [56] Assis, E.M., Olivieria, R.C., Moreira, L.E., Pena, J.L., Rodrigues, L.C., Machado-Coelho, G.L., Prevalência de parasitos intestinais na comunidade indígena Maxakali, Minas Gerais, Brasil, 2009 (Trans.) Prevalence of intestinal parasites in the Maxakali indigenous community in Minas Gerais, Brazil, 2009 Cad Saude Publica 29 (2013), 681–690, 10.1590/S0102-311X2013000400006.
57. [57] Coimbra, C.E. Jr., Santos, R.V., Welch, J.R., Cardoso, A.M., de Souza, M.C., Garnelo, L., Rassi, E., Follér, M.L., Horta, B.L., The first National survey of indigenous People's health and nutrition in Brazil: rationale, methodology, and overview of results. BMC Public Health, 13, 2013, 52, 10.1186/1471-2458-13-52.
58. [58] Ferreira, M.E., Matsuo, T., Souza, R.K., Aspectos demográficos e mortalidade de populações indígenas do Estado do Mato Grosso do Sul, Brasil (Trans.) Demographic characteristics and mortality among indigenous peoples in Mato Grosso do Sul State, Brazil Cad Saúde Pública 27 (2011), 2327–2339, 10.1590/S0102-311X2011001200005.
59. [59] Frydenberg, A.R., Graham, S.M., Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health 14 (2009), 1329–1337, 10.1111/j.1365-3156.2009.02375.x.
60. [60] Singla, R., Sharma, S.K., Mohan, A., Makharia, G., Sreenivas, V., Jha, B., Kumar, S., Sarda, P., Singh, S., Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 132 (2010), 81–86.
61. [61] Aguiar, G.F., Neves, W.A., Postmarital residence and within-sex genetic diversity among the Urubu-Ka'apor Indians, Brazilian Amazon. Hum Biol 63 (1991), 467–488.
62. [62] Mendes-Junior, C.T., Castelli, E.C., Meyer, D., Simões, A.L., Donadi, E.A., Genetic diversity of the HLA-G coding region in Amerindian populations from the Brazilian Amazon: a possible role of natural selection. Genes Immun 14 (2013), 518–526, 10.1038/gene.2013.47.
63. [63] Arias, I., Lecompte, N., Visbal, L., Curiel, I., Hernández, E., Garavito, P., Silvera-Redondo, C., Polimorfismo del Gen NAT2 en tres grupos indígenas de la región Caribe Colombiana (Trans.) NAT2 gene polymorphisms in three indigenous groups in the Colombian Caribbean coast region Colomb Med (Cali) 45 (2014), 148–153.
64. [64] Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., Komuta, K., Igarashi, T., Azuma, J., Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4 (2000), 256–261.
65. [65] Donald, P.R., Sirgel, F.A., Venter, A., Parkin, D.P., Seifart, H.I., van de Wal, B.W., Werely, C., van Helden, P.D., Maritz, J.S., The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 39 (2004), 1425–1430, 10.1086/424999.
66. [66] Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Lai, S.L., Yang, S.Y., Chang, F.Y., Lee, S.D., Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35 (2002), 883–889, 10.1053/jhep.2002.32102.
67. [67] Santos, N.P., Callegari-Jacques, S.M., Ribeiro Dos Santos, A.K., Silva, C.A., Vallinoto, A.C., Fernandes, D.C., de Carvalho, D.C., Santos, S.E., Hutz, M.H., N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis 17 (2013), 499–504, 10.5588/ijtld.12.0645.
68. [68] Rana, S.V., Sharma, S.K., Ola, R.P., Kamboj, J.K., Malik, A., Morya, R.K., Sinha, S.K., N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians. J Clin Pharm Ther 39:1 (2014), 91–96, 10.1111/jcpt.12105.
69. [69] Kinzig-Schippers, M., Tomalik-Scharte, D., Jetter, A., Scheidel, B., Jakob, V., Rodamer, M., Cascorbi, I., Doroshyenko, O., Sörgel, F., Fuhr, U., Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?. Antimicrob Agents Chemother 49:5 (2005), 1733–1738, 10.1128/AAC.49.5.1733-1738.2005.
70. [70] Donald, P.R., Parkin, D.P., Seifart, H.I., Schaaf, H.S., van Helden, P.D., Werely, C.J., Sirgel, F.A., Venter, A., Maritz, J.S., The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 63:7 (2007), 633–639, 10.1007/s00228-007-0305-5.
71. [71] Matsumoto, T., Ohno, M., Azuma, J., Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics 15 (2014), 601–607, 10.2217/pgs.14.38.
72. [72] Fretland, A.J., Leff, M.A., Doll, M.A., Hein, D.W., Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11 (2001), 207–215.
73. [73] Jorge-Nebert, L.F., Eichelbaum, M., Griese, E.U., Inaba, T., Arias, T.D., Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 12 (2002), 39–48 10.1097/00008571-200201000-00006.
74. [74] Lin, H.J., Han, C.Y., Lin, B.K., Hardy, S., Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 52 (1993), 827–834.
75. [75] Watanabe, J., Hayashi, S., Kawajiri, K., Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5’-flanking region. J Biochem 116 (1994), 321–326.
76. [76] Lee, S.W., Chung, L.S., Huang, H.H., Chuang, T.Y., Liou, Y.H., Wu, L.S., NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 14 (2010), 622–626.
77. [77] Chamorro, J.G., Castagnino, J.P., Musella, R.M., Nogueras, M., Aranda, F.M., Frías, A., Visca, M., Aidar, O., Perés, S., de Larrañaga, G.F., Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol 28 (2013), 323–328, 10.1111/jgh.12069.
78. [78] Seidegård, J., Ekström, G., The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 105:Suppl. 4 (1997), 791–799.
79. [79] Fukino, K., Sasaki, Y., Hirai, S., Nakamura, T., Hashimoto, M., Yamagishi, F., Ueno, K., Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33 (2008), 187–195 Erratum in: J Toxicol Sci 2008;33:667.
80. [80] Huang, Y.S., Su, W.J., Huang, Y.H., Chen, C.Y., Chang, F.Y., Lin, H.C., Genetic polymoprphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47 (2007), 128–134, 10.1016/j.jhep.2007.02.009.
81. [81] Roy, B., Chowdhury, A., Kundu, S., Santra, A., Dey, B., Chakraborty, M., Majumder, P.P., Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol 16 (2001), 1033–1037.
82. [82] Chatterjee, S., Lyle, N., Mandal, A., Kundu, S., GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther 35 (2010), 465–470.
83. [83] Leiro, V., Fernández-Villar, A., Valverde, D., Constenla, L., Vázquez, R., Piñeiro, L., González-Quintela, A., Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 28 (2008), 835–839, 10.1111/j.1478-3231.2008.01700.x.